Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding AV Therapeutics is 'Not Rated'. Macroaxis provides AV Therapeutics buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AVTH positions. The advice algorithm takes into account all of AV Therapeutics available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from AVTH buy-and-hold prospective. Check also Trending Equities.
For the selected time horizon AV Therapeutics has a risk adjusted performance of 0.0, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.0 and treynor ratio of 0.0We provide buy or sell recommendation to complement the latest expert consensus on AV Therapeutics. Our dynamic recommendation engine makes use of multi - dimensional algorithm to analyze the company potential to grow using all technical and fundamental data available at this moment. To make sure AV Therapeutics is not overpriced, please confirm all AV Therapeutics fundamentals including its EBITDA and the relationship between Book Value Per Share and Current Liabilities . As AV Therapeutics appears to be a penny stock we also recommend to validate its EBITDA numbers.
|AV Therapeutics is not yet fully synchronised with the market data|
|AV Therapeutics has some characteristics of a very speculative penny stock|
|AV Therapeutics has high likelihood to experience some financial distress in the next 2 years|
|The company currently holds 294.7K in liabilities. AV Therapeutics has Current Ratio of 0.3 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.|
|The entity reported previous year revenue of . Net Loss for the year was (776.15K).|
|AV THERAPEUTICS currently holds about 273.22K in cash with (1.03M) of positive cash flow from operations.|